Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 11:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–21 of 21 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: FluMist/B/Victoria Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Prospective Study to Evaluate the Safety of a New Monovalent Intranasal Influenza Vaccine

NCT00873912
View directory record Official record
Conditions
Healthy
Interventions
Monovalent influenza virus vaccine, Placebo
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
3
States / cities
Daytona Beach, Florida • Portland, Oregon • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2011 · Synced Sep 3, 2026, 11:27 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older

NCT06015282
View directory record Official record
Conditions
Influenza, Human
Interventions
Investigational aQIVc, licensed QIVr, licensed aQIV
Biological
Lead sponsor
Seqirus
Industry
Eligibility
50 Years and older
Enrollment
7,741 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
51
States / cities
Tempe, Arizona • Little Rock, Arkansas • Huntington Beach, California + 47 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Sep 3, 2026, 11:27 AM EDT
Completed Phase 1 Interventional

Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Mosaic Hexavalent Influenza Vaccine VRC-FLUMOS0116-00-VP (FluMos-v2) in Healthy Adults

NCT05968989
View directory record Official record
Conditions
Influenza
Interventions
VRC-FLUMOS0116-00-VP( FLUMos-v2)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 3, 2026, 11:27 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults

NCT01579916
View directory record Official record
Conditions
Influenza
Interventions
Trivalent Influenza Virus Vaccine, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
303 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
3
States / cities
Miami, Florida • Stockbridge, Georgia • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 2, 2014 · Synced Sep 3, 2026, 11:27 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults

NCT04576702
View directory record Official record
Conditions
Influenza, Human
Interventions
Investigational aIIV4c, IIV4c, aIIV4, RIV4
Biological
Lead sponsor
Seqirus
Industry
Eligibility
50 Years and older
Enrollment
471 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
21
States / cities
Mobile, Alabama • Tempe, Arizona • Jacksonville, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Sep 3, 2026, 11:27 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age

NCT06087640
View directory record Official record
Conditions
Influenza, Human
Interventions
aQIV or aTIV, QIV or TIV
Biological
Lead sponsor
Seqirus
Industry
Eligibility
65 Years and older
Enrollment
38,769 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
111
States / cities
Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 3, 2026, 11:27 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Immunogenicity of Quadrivalent Live Attenuated Influenza Vaccine (LAIV) in Children

NCT01091246
View directory record Official record
Conditions
Healthy or Stable Chronic Illness
Interventions
Q/LAIV (MEDI3250), FluMist/B/Yamagata, FluMist/B/Victoria
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
2 Years to 17 Years
Enrollment
2,312 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
110
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 95 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2011 · Synced Sep 3, 2026, 11:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Seasonal Influenza DNA Vaccine & Seasonal Influenza Trivalent Inactivated Vaccine (TIV) in Children & Adolescents

NCT01609998
View directory record Official record
Conditions
Influenza
Interventions
Seasonal Influenza DNA vaccine, TIV
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years to 17 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
5
States / cities
Atlanta, Georgia • St Louis, Missouri • Lebanon, New Hampshire + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Sep 3, 2026, 11:27 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Flucelvax (TIVc or QIVc) Pregnancy Registry

NCT03438487
View directory record Official record
Conditions
Influenza, Human, Pregnancy, Birth Defect
Interventions
Flucelvax Trivalent Influenza Vaccine, Flucelvax Quadrivalent Influenza Vaccine
Biological
Lead sponsor
Seqirus
Industry
Eligibility
Female only
Enrollment
692 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Sep 3, 2026, 11:27 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥50 Years of Age

NCT05501561
View directory record Official record
Conditions
Influenza, Human
Interventions
Experimental: IIV-A Investigational IIV-A administered as a single dose intramuscularly on Day 1, Experimental: aIIV-B Investigational aIIV-B administered as a single dose intramuscularly on Day 1, Experimental: aIIV-C Investigational aIIV-C administered as a single dose intramuscularly on Day 1, Active Comparator: Licensed IIV IIV administered as a single dose intramuscularly on Day 1
Biological
Lead sponsor
Seqirus
Industry
Eligibility
50 Years and older
Enrollment
1,056 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
47
States / cities
Tempe, Arizona • Huntington Beach, California • San Diego, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 3, 2026, 11:27 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Age and Prior Immunity to Response to Seasonal Influenza Vaccines in Children

NCT01246999
View directory record Official record
Conditions
Influenza
Interventions
Live attenuated Influenza vaccine, Trivalent Influenza Vaccine, TIV followed by LAIV, LAIV followed by TIV
Biological
Lead sponsor
University of Rochester
Other
Eligibility
2 Years to 9 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
2
States / cities
Lebanon, New Hampshire • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Sep 3, 2026, 11:27 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults

NCT01196975
View directory record Official record
Conditions
Influenza
Interventions
Quadrivalent seasonal influenza vaccine GSK2282512A, FluLavalTM-VB, FluLavalTM-YB
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
1,707 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
6
States / cities
Mesa, Arizona • Wichita, Kansas • Elkridge, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2018 · Synced Sep 3, 2026, 11:27 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4

NCT03318315
View directory record Official record
Conditions
Avian Influenza, Influenza, Influenza Immunisation
Interventions
AS03, Inactivated influenza H7N9 vaccine, Influenza Virus Quadrivalent Inactivated Vaccine, Phosphate Buffered Saline (PBS) diluent
Drug · Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years to 64 Years
Enrollment
149 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
4
States / cities
Birmingham, Alabama • Baltimore, Maryland • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Sep 3, 2026, 11:27 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Children

NCT01198756
View directory record Official record
Conditions
Influenza
Interventions
Quadrivalent seasonal influenza vaccine GSK2282512A, Fluarix™ VB, Fluarix™ YB
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months to 17 Years
Enrollment
3,109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
16
States / cities
Chandler, Arizona • Scottsdale, Arizona • Harrisburg, Arkansas + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2018 · Synced Sep 3, 2026, 11:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Seasonal Influenza HA DNA With Trivalent Inactivated Vaccine (TIV) Administered ID or IM in Healthy Adults 18-70 Years

NCT01676402
View directory record Official record
Conditions
Influenza
Interventions
Seasonal Influenza DNA vaccine, TIV
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
316 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
4
States / cities
Stanford, California • Iowa City, Iowa • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Sep 3, 2026, 11:27 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Development of Childhood Anti-Influenza Immunity

NCT03673345
View directory record Official record
Conditions
Influenza, Influenza Immunisation
Interventions
Influenza Virus Quadrivalent Inactivated Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 15 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Sep 3, 2026, 11:27 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age

NCT03143101
View directory record Official record
Conditions
Influenza, Healthy
Interventions
FluMist trivalent (2015-2016), FluMist Quadrivalent (2015-2016), FluMist Quadrivalent (2017-2018)
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
24 Months to 47 Months
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
12
States / cities
Savannah, Georgia • Bardstown, Kentucky • St Louis, Missouri + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2018 · Synced Sep 3, 2026, 11:27 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Immunogenicity of Quadrivalent LAIV (MEDI8662) in Adults 18 to 49 Years of Age

NCT00952705
View directory record Official record
Conditions
Healthy or Stable Underlying Chronic Medical Condition
Interventions
Q/LAIV-BFS (MEDI8662), FluMist/B/Yamagata, FluMist/B/Victoria
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
1,800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
18
States / cities
Mobile, Alabama • Sacramento, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 2, 2018 · Synced Sep 3, 2026, 11:27 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 Years

NCT01712984
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus Vaccine USP Quadrivalent, (Zonal Purified Subvirion) 2012 2013 Formulation, Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone Intradermal
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 64 Years
Enrollment
3,360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
38
States / cities
Hoover, Alabama • Huntsville, Alabama • Chandler, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated May 6, 2015 · Synced Sep 3, 2026, 11:27 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Evaluating the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRCFLUMOS0116-00-VP (FluMos-v2) With and Without ALFQ Adjuvant in Healthy Adults

NCT06863142
View directory record Official record
Conditions
Influenza Prevention, Seasonal Influenza
Interventions
VRC-FLUMOS0116-00-VP, ALFQ
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 3, 2026, 11:27 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age

NCT00860067
View directory record Official record
Conditions
Healthy or Stable Underlying Chronic Medical Condition
Interventions
Q/LAIV (MEDI3250), FluMist/B/Yamagata, FluMist/B/Victoria
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
1,800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
18
States / cities
Sacramento, California • San Diego, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2011 · Synced Sep 3, 2026, 11:27 AM EDT